Claim 55% Off TipRanks
- Unlock hedge fund-level data and powerful investing tools for smarter, sharper decisions
- Discover top-performing stock ideas and upgrade to a portfolio of market leaders with Smart Investor Picks
Zai Lab Ltd ( (HK:9688) ) just unveiled an update.
Zai Lab Limited announced that its Audit Committee will review and approve the company’s unaudited quarterly results for the third quarter of 2025 on November 6, 2025. Following the approval, the company plans to publish the results and hold a live earnings teleconference to discuss the outcomes, indicating a proactive approach to transparency and stakeholder engagement.
The most recent analyst rating on (HK:9688) stock is a Hold with a HK$22.00 price target. To see the full list of analyst forecasts on Zai Lab Ltd stock, see the HK:9688 Stock Forecast page.
More about Zai Lab Ltd
Zai Lab Limited is a biopharmaceutical company incorporated in the Cayman Islands, focusing on developing and commercializing innovative therapies. The company is listed on the Hong Kong Stock Exchange and is involved in the healthcare industry, primarily dealing with pharmaceutical products and services.
Average Trading Volume: 15,369,363
Technical Sentiment Signal: Sell
Current Market Cap: HK$25.45B
For an in-depth examination of 9688 stock, go to TipRanks’ Overview page.